These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 9834111)

  • 1. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
    J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W; He L; Cao X
    Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
    Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X
    Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of spontaneous metastatic lung cancer with tumor antigen-pulsed, interleukin-18 gene-modified dendritic cells].
    Chen J; Cao X; Xiu Q
    Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):779-82. PubMed ID: 11798964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
    Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
    Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
    J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
    Oh ST; Kim CH; Park MY; Won EH; Sohn HJ; Cho HI; Kang WK; Hong YK; Kim TG
    Vaccine; 2006 Apr; 24(15):2860-8. PubMed ID: 16443309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
    Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
    Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
    Yang S; Darrow TL; Vervaert CE; Seigler HF
    Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of antitumor immunity using bone marrow-generated dendritic cells.
    Porgador A; Snyder D; Gilboa E
    J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
    Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP
    Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
    Gabrilovich DI; Ciernik IF; Carbone DP
    Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
    Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.